Victoza will 'not be overnight success' in China
This article was originally published in Scrip
Executive Summary
Novo Nordisk does not expect its type 2 diabetes treatment Victoza (liraglutide) to become "a huge product overnight" in China, following approval of the drug by the State Food and Drug Administration (SFDA). However, it intends to use its "extensive experience and leadership market position" in China, where it has "70% of the insulin market", to boost uptake of the once-daily human glucagon-like peptide-1 (GLP-1) analogue, which is approved as an add-on to metformin or sulfonylurea, chief science officer Mads Krogsgaard Thomsen told Scrip.